A phase Ib/II trial of epitinib for treatment of non-small cell lung cancer with epidermal growth factor receptor activating mutations and brain metastasis

Trial Profile

A phase Ib/II trial of epitinib for treatment of non-small cell lung cancer with epidermal growth factor receptor activating mutations and brain metastasis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Epitinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 17 Aug 2016 New trial record
    • 02 Aug 2016 According to Chi-Med media release, company plans to present results from this trial at a scientific conference in late 2016.
    • 02 Aug 2016 According to Chi-Med media release, company targets to publish data from Phase Ib portion of this trial before the end of Q1 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top